← All trials
NCT01303926
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2010
- Primary completion
- Jun 1, 2012
- Completion date
- Jun 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 118
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Gruppo Oncologico Italia MeridionaleLead sponsor
- University of BariOverall official - principal investigator
- Giovanni Paolo II Oncology Institute, BariStudy director
- Gruppo Oncologico Italia MeridionaleReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.